Who Paid My Doc
David Fried
Internal Medicine East Greenwich, RI Medical Doctor
NPI 1275520678 CMS profile 239288
1598 S County Trl Ste 201, Suite 115, East Greenwich, RI 02818
General payments
$190
Research payments
$247,594
Ownership & investment interest
$0
Research they led as principal investigator
$37,160,668
Through program year 2025, David Fried of East Greenwich, RI is reported in the CMS Open Payments database as having received $190 across 3 general payments and $247,594 in research payments paid to them. Separately, studies naming them as principal investigator received $37,160,668 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $150 | 1 | |
| 2023 | General | $20 | 1 | |
| 2023 | Research | $198,727 | 25 | |
| 2022 | Research | $1,266 | 5 | |
| 2021 | General | $20 | 1 | |
| 2021 | Research | $39,490 | 4 | |
| 2020 | Research | $8,112 | 3 |
Beside peers
- David Fried
- Internal Medicine median
- Middle half of Internal Medicine
- National median
In program year 2025, general payments to David Fried were reported at $150. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.
Show as a table
| Year | David Fried | Internal Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $159 | $48–$570 | $163 |
| 2020 | $0 | $119 | $33–$402 | $114 |
| 2021 | $20 | $135 | $37–$521 | $132 |
| 2022 | $0 | $141 | $42–$496 | $149 |
| 2023 | $20 | $149 | $45–$519 | $160 |
| 2024 | $0 | $154 | $47–$537 | $164 |
| 2025 | $150 | $156 | $47–$551 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 115 drugsPart D claims
8,224
Drug cost
$431,662
Branded share of claims
13.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 61 | $57,103 | |
| Jardiance Empagliflozin | Brand | 56 | $50,885 | |
| Ozempic Semaglutide | Brand | 41 | $47,353 | |
| Amrix Cyclobenzaprine Hcl | Brand | 13 | $44,837 | |
| Trulicity Dulaglutide | Brand | 34 | $31,830 | |
| Xarelto Rivaroxaban | Brand | 36 | $26,375 | |
| Januvia Sitagliptin Phosphate | Brand | 18 | $19,673 | |
| Fioricet Butalb/Acetaminophen/Caffeine | Brand | 13 | $9,931 | |
| Atorvastatin Calcium | Generic | 763 | $8,737 | |
| Dulera Mometasone/Formoterol | Brand | 12 | $6,025 |
The 10 drugs with the highest cost, of 115 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 33 billing codesPaid by Medicare
$30,792
Medicare patients
278
Services billed
776
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 63% | |
| Diabetes | 27% | |
| Chronic kidney disease | 27% | |
| Depression | 25% | |
| Ischemic heart disease | 22% | |
| Cancer | 20% | |
| Atrial fibrillation | 17% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for influenza for injection into muscle 90662 | Office | 18 | 18 | $9 |
| Vaccine for influenza for injection into muscle 90653 | Office | 17 | 17 | $8 |
| Sarscov2 vac 50 mcg/0.5ml im 91322 | Office | 12 | 12 | $6 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
40 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Internal Medicine in Rhode Island
William Beliveau
Internal Medicine · Johnson, RI
Katarzyna Gilek-Seibert
Internal Medicine · Providence, RI
Randall Ingham
Internal Medicine · Providence, RI
Frank D'alessandro
Internal Medicine · Lincoln, RI
Gregory Allen
Internal Medicine · Cranston, RI
Richard Ruggieri
Internal Medicine · Providence, RI
Related records
Internal Medicine in Rhode Island
Practitioners in the same specialty and state, ranked by reported value.
All Internal Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Rhode Island
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.